Stocks
Bluebird Bio Financial Statements (BLUE) |
||||||||||
| Bluebird Biosmart-lab.ru | % | 2018 | 2019 | 2020 | 2021 | 2022 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 21.02.2019 | 18.02.2020 | 23.02.2021 | 04.03.2022 | 29.03.2023 | 07.11.2023 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 54.6 | 44.7 | 250.7 | 3.66 | 3.60 | 21.7 | |||
| Operating Income, bln rub | -572.0 | -812.1 | -629.5 | -590.9 | -287.1 | -136.2 | ||||
| EBITDA, bln rub | ? | -566.0 | -809.3 | -636.0 | -539.3 | -277.2 | -228.1 | |||
| Net profit, bln rub | ? | -555.6 | -789.6 | -618.7 | -562.6 | -266.6 | -78.4 | |||
| OCF, bln rub | ? | -413.4 | -564.4 | -470.4 | -635.6 | -353.0 | -277.5 | |||
| CAPEX, bln rub | ? | 55.7 | 76.3 | 29.0 | 23.0 | 13.2 | 8.95 | |||
| FCF, bln rub | ? | -469.2 | -640.6 | -499.3 | -658.6 | -366.2 | -286.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 622.7 | 853.8 | 874.9 | 529.9 | 275.7 | 277.7 | ||||
| Cost of production, bln rub | 0.885 | 2.98 | 5.40 | 38.9 | 10.1 | 23.9 | ||||
| R&D, bln rub | 448.6 | 582.4 | 588.0 | 319.9 | 240.8 | 179.8 | ||||
| Interest expenses, bln rub | 14.6 | 34.8 | 0.000 | 0.000 | 20.6 | 94.0 | ||||
| Assets, bln rub | 2 243 | 1 727 | 1 781 | 593.8 | 554.9 | 613.6 | ||||
| Net Assets, bln rub | ? | 1 885 | 1 285 | 1 355 | 374.3 | 196.3 | 222.5 | |||
| Debt, bln rub | 154.7 | 191.0 | 193.0 | 89.6 | 281.4 | 303.7 | ||||
| Cash, bln rub | 1 891 | 1 238 | 1 274 | 396.6 | 181.7 | 174.3 | ||||
| Net debt, bln rub | -1 737 | -1 047 | -1 081 | -307.0 | 99.6 | 129.4 | ||||
| Ordinary share price, rub | 64.3 | 56.8 | 28.0 | 9.99 | 6.92 | 3.07 | ||||
| Number of ordinary shares, mln | 52.0 | 55.2 | 62.2 | 68.9 | 78.6 | 109.1 | ||||
| Market cap, bln rub | 3 343 | 3 137 | 1 742 | 688 | 544 | 335 | ||||
| EV, bln rub | ? | 1 606 | 2 090 | 661 | 381 | 643 | 464 | |||
| Book value, bln rub | 1 859 | 1 258 | 1 332 | 369 | 186 | 212 | ||||
| EPS, rub | ? | -10.7 | -14.3 | -9.95 | -8.16 | -3.39 | -0.72 | |||
| FCF/share, rub | -9.02 | -11.6 | -8.03 | -9.56 | -4.66 | -2.63 | ||||
| BV/share, rub | 35.7 | 22.8 | 21.4 | 5.35 | 2.36 | 1.94 | ||||
| EBITDA margin, % | ? | -1 037% | -1 812% | -253.6% | -14 727% | -7 707% | -1 050% | |||
| Net margin, % | ? | -1 018% | -1 767% | -246.8% | -15 364% | -7 411% | -360.7% | |||
| FCF yield, % | ? | -14.0% | -20.4% | -28.7% | -95.7% | -67.3% | -85.5% | |||
| ROE, % | ? | -29.5% | -61.4% | -45.7% | -150.3% | -135.8% | -35.2% | |||
| ROA, % | ? | -24.8% | -45.7% | -34.7% | -94.8% | -48.0% | -12.8% | |||
| P/E | ? | -6.02 | -3.97 | -2.82 | -1.22 | -2.04 | -4.27 | |||
| P/FCF | -7.13 | -4.90 | -3.49 | -1.05 | -1.49 | -1.17 | ||||
| P/S | ? | 61.3 | 70.2 | 6.95 | 188.0 | 151.2 | 15.4 | |||
| P/BV | ? | 1.80 | 2.49 | 1.31 | 1.87 | 2.93 | 1.58 | |||
| EV/EBITDA | ? | -2.84 | -2.58 | -1.04 | -0.71 | -2.32 | -2.04 | |||
| Debt/EBITDA | 3.07 | 1.29 | 1.70 | 0.57 | -0.36 | -0.57 | ||||
| R&D/CAPEX, % | 804.8% | 763.8% | 2 028% | 1 391% | 1 823% | 2 008% | ||||
| CAPEX/Revenue, % | 102.1% | 170.7% | 11.6% | 628.2% | 367.2% | 41.2% | ||||
| Bluebird Bio shareholders | ||||||||||
